---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-031955"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:27:10.376889+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation

## Summary
- Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.
- James Lee, Controller since 2009, appointed Interim CFO and Interim Principal Accounting Officer effective July 13, 2024.
- Gerber will consult on financial and accounting matters through August 12, 2024 under prior agreement.
- Lee holds B.A. in Architecture from UC Berkeley and MBA from UIUC; previously accounting manager at Samsung.

## SEC filing metadata
- accession: 0001628280-24-031955
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/0001628280-24-031955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/cdxc-20240716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-031955
- JSON: https://secwatch.observer/filing/0001628280-24-031955.json
- Plain text: https://secwatch.observer/filing/0001628280-24-031955.txt

## Key facts
- Executive change
  James Lee was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer and Interim Principal Accounting Officer
  source text: On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/0001628280-24-031955-index.htm
- Executive change
  Brianna Gerber resigned as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..
  - Action: resigned
  - Role: Chief Financial Officer and Principal Accounting Officer
  source text: As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/0001628280-24-031955-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.